2022 ESG Report

Make a World of Difference

Catalyst pharmaceuticals

Published
May 2023

Table of Contents

Forward-looking Statement

This ESG Report contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2022 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

INTRODUCTION

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals ("Catalyst", "we", "our", or "Company") is a commercial-stage biopharmaceutical Company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. Our core product FIRDAPSE® (amifampridine) Tablets 10 mg, is U.S. Food and Drug Administration ("FDA") approved for treatment of Lambert-Eaton Myasthenic Syndrome ("LEMS") in patients 6 and older, a rare autoimmune condition that interferes with the ability of nerve cells to send signals to muscle cells.



In early 2023, we completed our agreement with Eisai Co., Ltd. ("Eisai") to acquire the United States' rights to FYCOMPA® (perampanel) CIII, the first and only FDA approved non-competitive anticonvulsant used to treat seizures in epilepsy patients. This acquisition aligns with our business development strategy and provides an opportunity to expand our product offerings and positively impact our patients. As this report addresses 2022 activities, FYCOMPA® and related activities are not addressed in this report.

Our Mission and Values

Through the development of novel therapeutics to treat rare diseases and our strong patient focus, Catalyst Pharmaceuticals provides life-changing medications for patients without adequate treatment options, thus filling a vital healthcare need. We strive to translate the tangible social benefits for our patients into growth for the Company through the pursuit of new pipeline platforms focusing on unmet medical needs.

In pursuit of this mission, our Company has three core values that guide corporate decisions: Passion, Trust, and Integrity:

1. **Passion** embodies the Company's commitment to engage, energize, and inspire others.
2. **Trust** signifies the commitment to live authentically with sincerity and honesty in all endeavors.
3. **Integrity** represents the commitment to the highest ethical standards, to lead with principles and to expect the very best from employees and the Company.

PASSION TRUST INTEGRITY



Company Profile

OVERVIEW:

HQ: Coral Gables, FL

2002 Founded

2006 Completed IPO

75 Full-time Employees

USA CAN MEX JPN

Commercialization rights in 4 countries

DRUG PORTFOLIO:

- Approved in 2018, **FIRDAPSE® (amifampridine) Tablets 10 mg** is the only evidence-based, FDA-approved treatment available for LEMS, and the first product approved for LEMS in more than 35 years.
- Expanding portfolio through 2023 acquisition of the U.S rights to **FYCOMPA® (perampanel) CIII**, the first and only non-competitive AMPA receptor antagonist approved by the FDA to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged 4 and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older.

OUR IMPACT:

- **FIRDAPSE®** has been used by over 1,000 unique patients since its launch.
- Named as one of America's Best Small Companies for 2023 by Forbes, ranking at 9 out of 100 from over 1,000 screened companies and building upon our positive impact as a ranked company in 2022.
- Named 2022 David J. Gury Company of the Year by BioFlorida, awarded for achieving significant milestones and contribution to the growth of Florida's life sciences industry.

INDUSTRY ASSOCIATION MEMBERSHIPS:

Bio · BIOFLORIDA · PPSWG Pharmaceutical Product Stewardship Work Group · GS1 · The International Pharmaceutical Supply Chain Consortium

CEO Letter

At Catalyst, we have built a sustainable business that aligns with our mission to deliver innovative medicines for patients living with rare diseases and operate under the fundamental principle of developing and commercializing best-in-class therapeutic drug products. With a strong patient-centric focus dedicated to a steadfast commitment to our patient community, we embarked on a comprehensive initiative to highlight the meaningful progress we are making as a sustainable Company with an ongoing commitment to continuous improvement.

In 2022, we formalized Catalyst's Environment, Social & Governance ("ESG") initiative with a focus on reporting our activities and progress on our Company's material ESG issues as part of our commitment to our stakeholders. This marks an important milestone in our ESG journey, which aligns with our business strategy to maximize opportunities and mitigate risks for sustainable growth.

Since our inception in 2002, Catalyst has operated on our three core values: Passion, Trust, and Integrity. We strive to maintain these ideals both personally and professionally. These attributes guide every decision and action we make as individuals and collectively as a Company.

Over the past several years, we have built strong and long-standing relationships with our patient community, fortified by the trust and value we deliver. With this patient-focused approach, our business relies on these strong ethical principles extending throughout our organization to enable better patient outcomes. As we strive to improve the lives of those who suffer from rare diseases, ensuring product quality and safety, efficacy, and access to healthcare are among our core ESG priorities.

In 2019, we launched our flagship product FIRDAPSE®, the only evidence-based, FDA-approved treatment for LEMS ("Lambert-Eaton Myasthenia Syndrome") in the U.S., addressing a significant unmet medical need for the treatment of this rare disease. At Catalyst, our priority is to put patients' needs first and to help ensure that all LEMS patients have uninterrupted access to FIRDAPSE®. In doing so, we have developed an array of financial assistance programs available to reduce patient co-pays and deductibles to a nominal, affordable amount. We also donate to qualified, independent charitable foundations dedicated to providing assistance to any U.S. LEMS patient in financial need, to support our goal that no LEMS patient is ever denied access to our medicine for financial reasons.

We believe our culture reflects our commitment to patient focus, and we value our employees' unique perspectives and contributions as our employees are Catalyst's greatest asset. Our low employee turnover is a testament to our people-first culture as we aim to equip our employees to succeed and flourish through competitive compensation plans, continuous employee engagement, financial assistance for continuing education and programs to create an equitable, diverse, growth-oriented, safe and healthy working environment. Most importantly, we seek those who share our core values as Catalyst believes that our achievements are a result of our employees' outstanding contributions, hard work, and dedication.

Honoring our core values of Passion, Trust, and Integrity, we are pleased to present our 2022 inaugural ESG Report. Our report aligns with the Sustainability Accounting Standards Board ("SASB") and Global Reporting Initiative ("GRI") frameworks and highlights our commitment to providing access to innovative medicines, regulatory activities, employee engagement, and responsibility to our stakeholders to drive sustainable growth.

As we progress on our ESG journey, we will continue to operate with our commitment to patients as the top priority and a sustained approach to all growth initiatives. We look forward to sharing further development of our ESG program in future reports.

Sincerely,

Patrick J. McEnany
Co-Founder, Chairman, and Chief Executive Officer

About this Report

Catalyst Pharmaceuticals is pleased to provide the Company's inaugural ESG Report, which outlines our practices, policies, and performance on relevant ESG issues during the fiscal year ending December 31, 2022. All data and discussion of performance included herein reflect Catalyst's operations in fiscal year 2022 unless noted otherwise.

Catalyst is committed to improving the lives of our patients, and our approach to embedding ESG risk management principles and performance considerations in our daily operations is underpinned by engagement with all stakeholders including our employees, patients, physicians, suppliers, and our shareholders.

Our inaugural ESG Report reflects Catalyst's most up to date activities to address relevant ESG issues, which has been guided by our identification of the ESG topics that are most material and germane to Catalyst's operations and value chain. The report and disclosures herein apply SASB and GRI frameworks, as well as alignment with the United Nations Sustainable Development Goals ("UN SDGs"). Additionally, to provide our stakeholders with the utmost transparency, where possible, we deploy both qualitative proof-points and quantitative key performance indicators ("KPIs").

The 2022 ESG Report cannot be considered a substitute for any material information included or disclosed in Catalyst's SEC filings such as, but not limited to, our Form 10-K, Form 10-Q, and Form 8-K. Any references to "material" or "materiality" in this report or related website content are not intended to have the same meaning as in the context of financial statements or financial reporting or as defined by the securities laws of the U.S. For purposes of this report, we follow the GRI definition of materiality for our ESG materiality assessment.

To provide feedback or submit questions regarding this report or Catalyst's ESG initiatives, please contact info@catalystpharma.com.

Our Approach to ESG

Materiality Assessment

We recognize that advancing a robust ESG program requires prioritization of the ESG matters most material to our business and resulting actions where we can have the largest impact on ESG issues. As such, we conducted our initial ESG materiality assessment to identify the foundation of our ESG strategy and related disclosures and performance updates included in this inaugural report. With the guidance of an experienced third-party ESG advisor, Catalyst identified its most material ESG topics via in-depth research of well-regarded materiality matrices and recommended disclosures from the likes of SASB, TCFD, rating agencies, direct stakeholder engagement, and much debate and discussion across our Company.

Following the identification of material topics across the Environmental, Social, and Governance pillars, Catalyst's internal leadership team was engaged to operationalize the prioritization of the Company's most material topics. Our identified material topics from our 2022 assessment are defined below:

Environment	Description
Emissions and Energy Management	Management/oversight, tracking, and reduction of energy consumption and scope 1-3 GHG emissions.
Waste Management	Management of hazardous and toxic waste and the ability to minimize waste through oversight and management.
Climate Strategy	Processes, practices, and goals that enable the Company to reduce its environmental impacts, improve transparency and public disclosures, and increase its operating efficiency.
Water and Effluents	Management of water usage, including the ability to reuse and recycle.

Social	Description
Access to Healthcare	Initiatives, pricing practices, and strategies to eliminate unjust, avoidable, and unnecessary barriers to accessible healthcare, thus creating a sustainable healthcare system in which every person has a fair opportunity to access care and medicines.
Product Quality and Safety	The efficacy of quality control, product testing, and resale processes, protocols, and efforts to preemptively address product defects and ensure products remain safe for patient use.
Human Rights	Efforts to respect, protect, and fulfill human rights and fundamental freedoms across our own and suppliers' operations, including compliance with applicable laws and internal standards.
Community Involvement	The frequency, focus, and efficacy of Company-sponsored volunteerism and community engagement efforts to strengthen local communities, support overall culture, and empower employees to support causes important to them and/or the organization.
Patient Safety	The processes and practices in place to prevent and reduce risks, errors, and harm to patients during provision of healthcare and clinical trials, ensuring positive health outcomes.
Human Capital	Management of our workforce through minimizing turnover and maximizing retention as well as successfully attracting and developing the level of talent and expertise needed to support our strategic growth plans. Additionally, this includes oversight, management, and transparent reporting of employees' health and safety with the goal of providing an overall incident-free workplace.
Supply Chain Management	Efforts to monitor, assess, and proactively mitigate risks – including those related to environmental and social matters – stemming from the supply chain to ensure resiliency in the event of supply chain disruptions.

Social	Description
Diversity, Equity, and Inclusion	Diversity, equity, and inclusion performance, programs, initiatives, and ability to track and report improvement over time to support an inclusive, diverse, and equitable organization.
Product Innovation	The ability to develop new, safe, and sustainable products to improve patient health.

Governance	Description
Executive Incentives	Compensation plan for executives and associated metrics including those linked to reaching ESG targets set by the Company in order to promote sustainability.
Board Composition	Our Board of Directors' independence, expertise, size, and general structure as well as demographic characteristics, such as gender, race, ethnicity, and age that will provide for diverse backgrounds, viewpoints, and perspectives.
Business Ethics and Transparency	Formalized processes, policies, and oversight structures in place to ensure the Company and its employees are operating ethically, in line with applicable regulations, and that reporting of unethical behavior is encouraged.
Shareholder Rights	Practices related to shareholder engagement and the provision of voting rights, rights to call special meetings, appoint directors, and act by written consent.
Regulatory Preparedness	Proactive monitoring and tracking of potential regulatory changes and its ability to adhere to any new legislation or regulation which may impact its business activities or create new reporting obligations.
Data Privacy and Security	Practices, compliance procedures, and oversight mechanisms in place to identify and limit illegal and unethical use of personal employee, patient, and vendor data.
Ethical Marketing	Formal practices, policies, and oversight mechanisms to ensure products are accurately and transparently marketed and advertised to customers and business partners.
ESG Oversight	Explicit Board and management-level oversight of and responsibility for ESG initiatives, along with the efficacy of oversight structures in place to drive change, advance the Company's ESG strategy, and achieve our ESG targets.

International Rare Disease Day

In February 2022, Catalyst was provided with the opportunity to stand with the National Organization for Rare Disorders ("NORD"), Global Genes, Muscular Dystrophy Association, Myasthenia Gravis Foundation of America, Conquer MG, and Myasthenia Gravis Association, to ring the opening bell of the Nasdaq market to acknowledge international Rare Disease Day. We are proud of our efforts to stand with the LEMS community and patient advocacy groups to call attention to the need for collaboration to encourage research and development of orphan drugs to bring new treatments to market for rare diseases that affect small patient populations.

We returned to ring the Nasdaq closing bell in partnership with leading advocacy groups for International Rare Disease Day in February 2023 to shed light on the important unmet need for diagnosis and treatment of rare diseases.

Photograph courtesy of Nasdaq, Inc.

Catalyst Named as One of America's Best Small Companies by Forbes

Catalyst is proud to be ranked ninth on Forbes 2023 list of America's Best Small Companies. We believe our place on this list highlights our steadfast commitment to our patients and ability to thrive as a company. We strive to demonstrate leadership in our industry with our efforts to support the LEMS community and advocate for rare disease research.

ESG Oversight & Business Ethics

ESG Oversight

With clear oversight of ESG at the Board level, the responsibilities of the Compensation Committee, Audit Committee, and Nominating and Corporate Governance Committee include oversight and review of portions of Catalyst's ESG strategies, initiatives, and policies relevant to their duties to mitigate risk and capitalize on available opportunities.

COMPENSATION COMMITTEE

Responsible for evaluating and approving compensation plans, and ensuring fair and equitable pay for all employees, including executives

AUDIT COMMITTEE

Manages and facilitates the risk management function, ensuring risks associated with financial reporting, operations, and ESG are addressed with properly functioning controls

NOMINATING AND CORPORATE GOVERNANCE COMMITTEE

Identifies and selects Board members, ensuring each member supports ESG objectives and is capable of performing delegated ESG oversight responsibilities

Additionally, Catalyst has created a Corporate Responsibility Steering Committee comprised of our Chief Legal and Compliance Officer, Chief Financial Officer, and Vice President of Investor Relations. The Committee was enacted to assess Catalyst's current status on ESG issues, address any disclosure gaps on those issues, and begin putting in place policies and practices to set goals, monitor activities, and manage the process for addressing issues in these areas. The group regularly engages the Board, relevant committees, executives, and cross-functional department stakeholders to report ESG progress and leverage Catalyst's bench of healthcare experience to continue maturing our program.

Various employees throughout Catalyst have ESG responsibilities integrated into their roles. These employees are subject matter experts tasked with gathering data and assessing activities related to ESG initiatives related to their roles. Our Patient Advocacy team takes the lead in our patient advocacy group activities, including gathering information and setting goals. They work alongside our Patient Services team, who manage Catalyst Pathways®, to support our patients throughout their treatment journey. Our Manufacturing team manages our relationships with contract manufacturers, and obtains ESG data from manufacturers. Our Human Resources team manages diversity, equity, and inclusion, as well as other employee related activities. Employees on our Quality team manage information related to quality outcomes.

ESG Oversight Responsibilities Across Our Organization

Business Ethics and Transparency

In our mission to make a meaningful difference in patients' lives with the highest manner of integrity, Catalyst is committed to creating and promoting high ethical, moral, and legal principles. Our ethical principles are underpinned by our Code of Conduct and Business Ethics which was adopted by the Board of Directors and guides all employees and Board Members to prevent missteps, encourage compliance with governmental laws and regulatory requirements, and discourage corrupt corporate behavior. Specifically, our Code establishes the following principles:

- Promote compliance with all relevant governmental laws, rules and regulations;
- Promote honest and ethical conduct, including the handling of actual or apparent conflicts of interest;
- Promote full, fair, accurate, timely and clear disclosures in all Company reports and public filings and communications made by Catalyst;
- Promote the protection of Catalyst's assets;
- Promote fair practices within the marketplace and deter wrongdoing; and
- Provide for timely reporting of all potential or actual violations of the Code.

ALL CATALYST EMPLOYEES ARE REQUIRED TO UNDERSTAND, COMPLY WITH, AND REPORT ANY SUSPECTED VIOLATIONS OF THE CODE.

Employee Training

We recognize establishing a strong ethics program across our organization requires employee training and regular engagement. As such, we train 100% of our employees on our Code of Business Conduct and Ethics on an annual basis. Notably, all Medical Affairs and Commercial employees are required to participate in an initial training on the Code of Business Conduct and Ethics given our focus on proper conduct within the healthcare community.

Practicing Ethical Responsibility in the Healthcare Community

Catalyst employees are required to act with integrity and observe the highest ethical standards of business conduct in their dealings with Catalyst's patients, physicians, customers, and any additional stakeholders with whom they interact when performing their jobs. To this end, our Code of Business Conduct and Ethics sets high standards for interactions with physicians and patients, professional conduct, and representation of clinical trial data, including avoiding potential misrepresentations of facts. We also provide training for our employees on expectations that must be met during interactions with health care professionals to comply with the PhRMA Code on Interactions with Health Care Professionals (the "Code"). The Code reinforces how interactions with health care professionals are professional exchanges designed to benefit patients and enhance the practice of medicine.

In the event a potential violation is reported, an investigation would be launched to determine if any violations occurred. In the case of violations, Catalyst would institute corrective and/or disciplinary actions.

Bribery & Corruption

We are proud to report zero monetary losses as a result of legal proceedings or investigations associated with bribery and corruption allegations. Catalyst also has not had any investigations or proceedings that it engaged in any behaviors that promote anti-competitive, anti-trust, and monopolistic practices.

Our Code of Business Ethics and Conduct explicitly states that all personnel employed by Catalyst must adhere to the U.S. Foreign Corrupt Practices Act and must not accept or offer any gifts to government personnel. Employees are given training upon hire and bi-annually devoted to anti-corruption policies and procedures as well as legal actions for this behavior, anti-trust, and monopoly practices ensuring compliance with these guidelines.

Whistleblower Protections

Our employees' and organization's responsibility to ethics and compliance has self-accountability as its foundation, as we encourage our personnel to hold each other accountable by reporting critical concerns or violations of our Code. Any Catalyst personnel who reasonably believes that there has been a material violation of our Code is required to report the potential violation to their supervisor, Chief Compliance Officer, Chief Financial Officer, Chief Executive Officer, and/or the Lead Director of the Board of Directors.

Additionally, whistleblower or external reports of ethical concerns can be made electronically via our EthicsPoint webpage including anonymous reporting options. Catalyst ensures that there will be no adverse action taken against employees, or others, for reporting violations of the Code in good faith.

IN 2022, CATALYST HAD ZERO MONETARY LOSSES OR PAYMENTS AS A RESULT OF LEGAL PROCEEDINGS ASSOCIATED WITH FALSE MARKETING CLAIMS.

Ethical Marketing

Catalyst is committed to fair and ethical conduct and compliance with all laws and regulations. Our Code of Business Conduct and Ethics addresses a wide range of business activities for our employees and sets forth basic principles to provide further guidance and ensure adherence. Specifically, our Code of Business Conduct and Ethics includes high standards specific to interactions with physicians and patients, professional conduct, representation of clinical trial data, and steps to take to avoid any potential misrepresentations of facts. All Medical Affairs and Commercial employees are required to participate in Code training upon joining the Company – which explicitly covers labeling and promotion – in addition to routine follow-up trainings.

SOCIAL

Product Quality & Patient Safety

As represented in our mission statement, Catalyst is committed to improving the lives of those who suffer from rare diseases. Through innovative research and development practices, robust quality standards, and comprehensive safety procedures, we are able to follow through on our promise to provide patients with safe and effective drugs.

Drug Safety

Testing and Quality Standards

Catalyst works hard every day to demonstrate the position that medication should be safe, effective, and easy to use. We understand the role that our product plays in improving patients' lives and therefore we work rigorously to ensure we produce high quality products. All Catalyst products are subject to extensive testing protocols to verify that each batch meets the appropriate standards for purity, potency, and quality prior to release for use. To ensure we are upholding our promise to patients, we require our manufacturing vendors to meet all appropriate Good Manufacturing Practices ("GMP") in their management and manufacture of Catalyst goods and ingredients. In addition, Catalyst supports and facilitates oversight of manufacturing, testing, and quality processes by appropriate governance agencies to receive unbiased validation and feedback on our approach.

To supplement our product safety procedures, we work vigorously to detect and resolve any potential quality control issues. Our contingency plans and mitigation control systems ensure Catalyst can continue to provide safe products to patients in the case of a disruption that may affect product quality or supply. Catalyst addresses potential issues at the source by dispersing finished goods at various locations, thus minimizing the potential for a significant amount of stock to be compromised. We also maintain an appropriate level, based on historic usage, of safety stock to ensure patients can continue to receive their necessary life-saving drugs without disruption. Our quality control efforts enable our ability to continuously provide safe and effective products to our patients.

Product Incidents

As a result of our committed efforts to produce high-quality and safe products, we can confidently affirm that Catalyst products were not subject to any product recalls in 2022, including recalls in non-U.S. markets and those not subject to FDA reporting. In addition, no drugs or products developed by Catalyst were listed in the FDA's MedWatch Security Alerts for Human Medicinal Products database and the FDA staff in the Center for Drug Evaluation and Research ("CDER") and the Center for Biologics Evaluation and Research ("CBER") have not identified any potential safety issues in Catalyst drugs and products.[1] There were also no FDA enforcement actions or similar actions by any regulatory agencies in response to violations of current Good Manufacturing Practices in 2022.

In 2022, there were 29 fatalities reported among FIRDAPSE® patients in the U.S. and Canada. Out of the 29 total fatalities, there were 0 cases with possible attribution to FIRDAPSE®. None of the remaining cases were determined to be attributable to FIRDAPSE®. It is important to note that there is a high prevalence of cancer comorbidities – approximately 50% – and other autoimmune comorbidities present in LEMS patients. For additional information, refer to our Form 10-K.

Catalyst strives to consistently achieve best practices throughout the value chain from manufacturing through disposal. In the fall of 2021, we became a proud member of the Pharmaceutical Product Stewardship Work Group ("PPSWG"), an organization that is committed to providing infrastructure, guidance, and subject matter expertise to support member compliance and improve awareness of existing pharmaceutical disposal options at the consumer level. Through our membership in this organization, we actively stay up to date on best practices as well as legislative and regulatory updates in the pharmaceuticals industry. Given the recent initiation of these efforts, we are unable to provide the amount of unused product that was accepted through takeback initiatives in 2022. In addition, in rare instances in which a product is returned to a Specialty Pharmacy by the patient or others, Catalyst will pay for the destruction of the product. These initiatives and processes ensure we are doing our part to reduce the potential for diversion, protect our water, and prevent improper use of medications.

1. As of March 2023.



Patient Safety

At Catalyst, we believe partnering with patients is our first priority. We are dedicated to providing the necessary resources and knowledge to empower and strengthen patients to manage and improve their conditions. We believe that when patients take an active role in their healthcare, make informed decisions, and participate in research, not only may they improve their own health but also the health and lives of others. This is why patient safety and proactively seeking patients' perspectives is a central component in our decision-making process. We are committed to ensuring patient safety from clinical trials through commercialization of our products.

Safety of Clinical Trial Participants

Our therapeutic area of concentration is Lambert-Eaton Myasthenic Syndrome. In 2022, Catalyst's only clinical trial activities were conducted in the United States and focused exclusively on LEMS. Contract research organizations ("CRO") are used in a very limited fashion in the U.S., primarily for single tasks within the trial management process such as identifying sites, setting up a trial master file, and performing statistical analysis. Catalyst directly manages all other aspects of the study.

Selecting Clinical Trial Participants

The process of obtaining informed consent from participants in clinical trials is specific to the study and site in focus. We provide for each study a template for Informed Consent Forms ("ICF") in addition to the detailed protocol. Note, each ICF is developed in accordance with each site's requirements and their Institutional Review Board ("IRB"). Further, we ensure that the minimal elements of informed consent are contained in each site's version, and we complete site audits to confirm documentation, verify that the necessary steps are being followed, and ensure that the ICFs at each site are up to date with current study information.

Safety of Clinical Trials

Catalyst maintains clinical trial safety on an ongoing basis through controlled processes, policies, standard operating procedures, and an overall document management system. Each of our clinical trials and commercial products is reviewed from a medical and overall safety perspective utilizing highly targeted standard operating procedures. Catalyst's Pharmacovigilance Group follows similar standard processes, policies, standard operation procedures, in conducting safety surveillance, investigations, and reporting across all of our operations, including medical surveillance post-clinical trials. Safety procedures include an annually updated safety report submitted to regulatory authorities, including the FDA, and a thorough assessment of any Serious Adverse Events that are reported from clinical trial sites or patients.

Catalyst leverages the mechanisms described in our Standard Operating Procedures specific to vendor qualification and vendor management to ensure that all vendors involved in clinical trial activities meet the requirements outlined in relevant national and international standards such as the ICH guidelines, FDA regulations pertaining to Good Clinical Practices ("GCP"), all trial subject protections from the Helsinki Declaration, as well as other comparable resources, references, and requirements. Catalyst also leverages Standard Operating Procedures that govern our vendor qualification, related requirements and tracking, our GxP audit planning and execution – specifically including manufacturing and clinical trial quality audits – and our overall quality management plan. We also ensure all clinical trial staff is trained appropriately to uphold the standards outlined in our Standard Operating Procedures. Collectively, our Standard Operating Procedures describe a set of standards for quality and safety, as well as a process to monitor and initiate corrective actions, as necessary.

Catalyst provides patients with access to its products through compassionate use supplies that are a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product or an investigational use for an approved product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Formal requests for compassionate use access to Catalyst products in development may only be made by licensed prescribers with the authority to administer and oversee treatment of patient(s) on whose behalf the request is made. All requests must include documentation and are reviewed by the Catalyst Chief Medical Officer based on a two-part analysis that addresses if the product is appropriate for compassionate use access and if the patient is an appropriate recipient for compassionate use access. Catalyst believes granting this option to patients aligns with our goal of providing patients with resources to empower themselves to manage their conditions.

FOR ADDITIONAL INFORMATION, PLEASE REFER TO OUR COMPASSIONATE USE POLICY AVAILABLE ON OUR WEBSITE.

In 2022, there were no FDA Sponsor Inspections, or any inspections by other regulatory agencies related to clinical trial management and pharmacovigilance. Therefore, there were no findings that resulted in a classification of Voluntary Action Indicated ("VAI") or Official Action Indicated ("OAI"). In addition, Catalyst has not been involved in any legal proceedings associated with clinical trials in any countries. As a result, we have not incurred any related monetary losses in 2022.

Patient Safety for Market Stage Products

Catalyst believes in the importance of protecting patient safety from clinical trials through to commercialization of our products. This includes adhering to regulations, monitoring product quality and efficacy, and providing patients with the support they need. To date, Catalyst has treated over 1,000 unique patients with FIRDAPSE®. We are proud of our efforts in this area to help those living with LEMS take control of their condition.

As part of the approval of our product, FIRDAPSE® for LEMS, the FDA required us to conduct a clinical trial to evaluate the effect of hepatic impairment on the exposure of amifampridine after oral administration of FIRDAPSE® relative to that in subjects with normal hepatic function. This study was completed and submitted to the FDA. The FDA also required us to perform a second carcinogenicity study of amifampridine phosphate in mice, which we have completed and submitted to the FDA.

For continuous monitoring of market stage products, Catalyst maintains a pharmacovigilance ("PV") department that specializes in post-marketing surveillance and pharmacovigilance. The pharmacovigilance department is responsible for the facilitation of various programs that support the monitoring of our product to ensure long-term safety and efficacy. As part of our monitoring activities, Catalyst established a pregnancy surveillance program to collect and analyze information for a minimum of ten years on pregnancy complications and birth outcomes related to FIRDAPSE®. In 2022, we also operated a NAT2 testing program to provide physicians with patients nucleic acid testing ("NAT") genetic status. This program assisted physicians in devising a tailored titration program for LEMS patients, increasing the quality of their care. As a result of these monitoring activities, physicians are able to better prescribe our products, as needed, to better serve their and our patients.

Patient Advocacy

In addition to meeting FDA regulations and monitoring the safety of administered products, we believe that supporting and advocating for patients is key to ensuring their safety and better health outcomes. We are inspired by the courage of individuals facing the unique challenges of living with rare neurological diseases, and the perspective of those affected by these conditions is paramount to our work. At Catalyst, we work closely with patient organizations to integrate voices from the patient community into our regular business engagement. Engagement with leaders in the patient advocacy community allows us to better understand their perspectives and learning from these interactions helps us inform our policy and advocacy activities. We also work hard for rare disease patients to connect with each other – where they can share their experiences and stories, as many LEMS patients have never met another LEMS patient. This helps foster a sense of community among rare disease patients to help them connect and manage their disease through mutual support.

We are taking initiative with various internal programs that allow for information sharing, leading to better monitoring of patients and refinement of support processes moving forward. Continuous patient support through knowledge sharing and research ensures that patients have the power to manage their conditions.

Our patient engagement team is the champion within Catalyst for the community voice and leads external communications with advocacy organizations. From supporting efforts to educate and raise awareness for key patient issues to developing and sharing educational programs and materials, our team continuously works to connect individuals and families impacted by rare diseases with each other and relevant support organizations.

"THE CHANCE FOR ME TO WALK MY DAUGHTER DOWN THE AISLE AND EVEN DANCE WITH HER ON HER WEDDING DAY AFTER ALL I HAVE GONE THROUGH – THAT WAS AMAZING. YOU SHOULD HAVE SEEN US, I WAS SPINNING HER LIKE FRED ASTAIRE." – BILL (FIRDAPSE® CLINICAL TRIAL PATIENT)



Catalyst supports the following organizations dedicated to helping people with rare diseases:

Global Genes is a leading rare disease advocacy organization with global reach to the worldwide rare community of patients, caregivers, advocates, and clinical partners. Its mission is to eliminate the challenges of rare disease. Learn More

Part of the Global Genes community, LivingwithLEMS.org is a site for all patients with LEMS and their caregivers and family members that offers information, resources, and support. The goals of this site are to build connections and offer resources and support to help LEMS patients become informed advocates. Learn More

Established in the late 1970s and early 1980s, the National Organization for Rare Disorders ("NORD") is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 260 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services. Learn More

Established in June 1950, the Muscular Dystrophy Association is committed to saving and improving the lives of kids and adults living with muscular dystrophy, amyotrophic lateral sclerosis (ALS), and related muscle-debilitating diseases that take away physical strength, independence, and life. Learn More

The Myasthenia Gravis Foundation of America is the only national volunteer health agency in the United States dedicated solely to the fight against myasthenia gravis. MGFA is committed to finding a cure for myasthenia gravis and closely related disorders, improving treatment options, and providing information and support to people with myasthenia gravis, through research, education, community programs, and advocacy. Learn More

On Rare Disease Day in February 2022, Catalyst teamed up with patients and advocacy groups to help raise awareness of the important need for new treatments for rare diseases that affect small patient populations. As part of this campaign, we launched a podcast called LEMS Aware. Produced by Catalyst and created to increase awareness of and connections in the LEMS community, the podcast discusses topics unique to LEMS and the rare disease community as a whole. Participants in the podcast include LEMS patients, physicians, and influencers in the rare disease community. We believe the podcast will help meet our goal of providing resources and educating the LEMS community. This podcast will also assist patients in getting answers to many of their questions and provide an open forum to facilitate conversation and knowledge sharing. To access the LEMS Aware podcast, please visit the LEMS Aware website.

Product Innovation

Catalyst conducted an extensive clinical development program for FIRDAPSE® and retains the skill and experience to continue to do this for other products. The core mission of Catalyst's development program is to advance the treatment for patients living with rare, debilitating neuromuscular and neurological diseases. We believe that no other field of medicine holds as much promise and makes such a significant impact on patients' lives as the development of novel rare disease drugs.

Steps of Drug Development

DISCOVERIES

Researching possible new methods to treat disease
Developing or discovering new molecules, technology, or new uses for existing medicines

NONCLINICAL TESTING

Determines safety and shows effectiveness in the target disease
Animal testing obtains safety data about effects on multiple internal organs and proves potential efficacy of the compound

Clinical Trials
Many research studies are done in people to evaluate the medicine's efficacy and safety

PHASE 1

Tests the safety of the medicine
The safety is carefully tested in healthy volunteers, people with kidney or liver problems, and sometimes in people with the rare disease. Even more studies seek information about how and when the medicine reaches specific body tissues

PHASE 2

More studies in people living with the rare disease
Tests if the medicine works in people with the condition and determines potential side effects and best dose

PHASE 3

Compares participants receiving the new medicine to those in the control group
The control group may receive a placebo (an inactive medicine) or the current standard treatment

Approval

PHASE 4

Post-marketing surveillance and pharmacovigilance
Monitors the product for long-term safety and efficacy

Drugs in Portfolio and in R&D

Current Portfolio

During 2022, Catalyst had one approved product, FIRDAPSE®, the only FDA approved treatment of LEMS in adults and pediatric patients six years of age and older. FIRDAPSE® is a potassium channel blocker clinically proven to maintain muscle strength and mobility in LEMS patients. The FDA granted FIRDAPSE® breakthrough therapy designation to expedite the drug development process and furthermore granted FIRDAPSE® orphan drug designation, a designation granted to drugs that are expected to provide a significant therapeutic advantage over existing treatments and that targets conditions affecting 200,000 or fewer patients in the United States annually. Our orphan drug designation for FIRDAPSE® is a differentiator from other pharmaceutical companies and highlights our efforts to meet our goal of delivering innovative drugs for rare diseases. We are proud of our ability to provide patients with a product that makes an impactful and positive difference in their health and livelihood. In early 2023, Catalyst acquired a second approved product, FYCOMPA® (perampanel) CIII, approved by the FDA for use with patients with certain seizure conditions.

Research and Development

Catalyst is investing in the science of possibility – discovering, developing, and delivering innovative, life-changing medicines and solutions to transform patients' lives and address their most important unmet medical needs. We are laser-focused on developing therapies for rare neuromuscular and neurological disorders, as we believe this is where we can have the greatest impact on patients' lives.

At Catalyst, our mission is to develop and commercialize innovative therapies for people with rare debilitating neuromuscular and neurological diseases. To execute this mission, we gather the best ideas, utilize leading-edge science, and partner with leaders in their respective fields.

While our flagship product , FIRDAPSE®, is currently marketed in the United States by Catalyst and in other territories by other companies. Catalyst has plans to seek approval from the FDA to increase the approved maximum daily dosage. In the past year, we expanded our LEMS approval to include pediatric patients ages six and older. This is an exceptional accomplishment, as communicated by Catalyst Chairman and CEO, Patrick J. McEnany:

> "WE ARE VERY PLEASED TO HAVE RECEIVED FDA APPROVAL FOR THE EXPANDED PEDIATRIC INDICATION FOR FIRDAPSE®. WHILE THE U.S. LEMS PEDIATRIC POPULATION IS AN EXCEPTIONALLY SMALL NUMBER OF PATIENTS, THIS POSITIVE OUTCOME HELPS ENSURE THAT ALL ELIGIBLE LEMS PATIENTS HAVE ACCESS TO FIRDAPSE® FOR THE TREATMENT OF THIS RARE DISEASE. THIS MILESTONE REPRESENTS OUR LONG-STANDING AND UNWAVERING COMMITMENT TO THE LEMS PATIENT COMMUNITY, AND WE ARE PLEASED THAT THIS MEDICINE IS NOW AVAILABLE FOR THIS IMPORTANT PATIENT POPULATION."

In the past five years, Catalyst has explored and/or pursued research and development activities for the use of FIRDAPSE® to treat various rare diseases including:[2]

- Lambert-Eaton Myasthenic Syndrome ("LEMS");
- Myasthenia Gravis ("MuSK-MG");
- Congenital Myasthenic Syndrome ("CMS");
- Spinal Muscular Atrophy ("SMA"); and
- Hereditary Neuropathy with Liability to Pressure Palsies ("HNPP").

Regardless of the success of these studies, Catalyst holds a steadfast willingness to commit funding for further clinical trials. Outside of LEMS, we are currently not pursuing approval for the use of FIRDAPSE® for these diseases due to the lack of available data. However, we supported compassionate use for FIRDAPSE® in MuSK-MG, CMS, SMA, and Downbeat Nystagmus ("DN").

We will continue to pursue rare disease research opportunities to ensure we remain at the forefront of innovation with a continued focused on evaluating potential opportunities to add to our portfolio. Notably, Catalyst is a member of various organizations, including the Biotechnology Innovation Organization ("BIO") and BioFlorida, which support advocacy and medical research.

Biotechnology Innovation Organization

The Biotechnology Innovation Organization is the world's largest advocacy organization representing member companies, state biotechnology groups, academic and research institutions and related organizations across the world.

BIOFLORIDA

BioFlorida represents Florida's life sciences industry and 8,600 establishments and research organizations in BioPharma, MedTech, Digital Health, and Health Systems. BioFlorida's member driven initiatives provide a strong business climate for the advancement of innovative products and technology that improve lives and promote economic benefits to the state. In 2022, Catalyst was named by BioFlorida as the 2022 BioFlorida Company of the year.

Through our involvement in these organizations, we ensure Catalyst is up to date on all industry trends and is continuing on the journey to develop innovative rare disease products.

2. This does not include Endo Ventures Limited's Sabril® (vigabatrin) which has yet to receive abbreviated new drug application approval.

Strategic Collaborations

In 2012, Catalyst entered a strategic collaboration for the North American rights of FIRDAPSE® with BioMarin Pharmaceutical Inc. ("BioMarin"), a company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin previously held the worldwide rights to FIRDAPSE® and sold the product in the European Union ("EU"). In January 2020, BioMarin advised us that they transferred certain of their rights to SERB SA. Under the new agreement, Catalyst makes certain royalty payments on net sales of FIRDAPSE® to SERB SA. Catalyst's current licensing rights for amifampridine phosphate cover North America and Japan. Under our current agreement, we also have the option to further expand our commercial territory to include most of Asia, as well as Central and South America, upon performance of milestones in Japan.

In 2021, we made a strategic decision to broaden and diversify our product portfolio through acquisitions of both early and late-stage products or companies or technology platforms in rare disease therapeutic categories focused on rare disease opportunities outside of oncology. In the same vein, we are employing a disciplined approach to evaluating assets as we believe strategic expansion will better position our Company to develop a more diversified portfolio of drug candidates. However, there can be no assurance that drug candidates or technology platforms we acquire, if any, will be successfully developed or commercialized.

We are currently exploring several potential opportunities to in-license or acquire drug products in development or acquire companies with drug products in development. As part of our commitment to diversify our portfolio with innovative medicines that address important unmet needs for patients who often have limited or no therapeutics options, in January 2023, Catalyst acquired the U.S. commercial right of FYCOMPA® (perampanel) CIII, an established commercial stage epilepsy asset. The acquisition expands the Company's commercial portfolio with an established U.S. market product. The Company remains dedicated to growth within neurology and will continue to actively pursue synergistic adjacencies.

Supply Chain Management

Catalyst currently interacts with North American and Japanese markets, holding distribution rights to amifampridine phosphate in the United States and Mexico and sublicensing the rights for Canada and Japan to other entities. Catalyst is licensed in Florida as a virtual drug manufacturer, and as such we do not own or operate any manufacturing facilities. We rely on contract manufacturers and packagers to produce our products, each of which is based in North America. We are confident in the ability of our contractors to consistently deliver our research materials and commercial products that meet our quality standards. Therefore, we do not have plans to build or acquire in-house manufacturing capabilities.

To ensure our high quality and safety standards are upheld throughout the supply chain, we conduct supplier assessments and supplier training. We also are members of various pharmaceutical supply chain standard setting organizations, ensuring we remain up to date on best practices that are essential in protecting the quality and traceability of our product.

WHEN SELECTING SUPPLIERS, WE CONDUCT THOROUGH ASSESSMENTS TO ENSURE POTENTIAL SUPPLIERS DEMONSTRATE AN ABILITY TO UPHOLD OUR STANDARDS.

Assessing Suppliers

Catalyst values working with suppliers that hold similar values as our Company regarding product quality, safety, and commitment to best practices. When selecting suppliers, we conduct thorough assessments to ensure potential suppliers demonstrate an ability to uphold our standards. All selected contractors are inspected by the FDA to demonstrate that they are in substantial compliance with federal regulations. In addition, all manufacturers must demonstrate to us on a regular basis that they are in compliance with the FDA's current Good Manufacturing Practices regulations and our related policies. We contract with third parties to manufacture our products and our contract manufacturers are required to comply with all applicable environmental laws and regulations that affect the manufacturing process. As a result, we do not believe that we will have any significant direct exposure to environmental issues.

Supplier audit programs are used to conduct continuous monitoring of supplier practices. Out of our Tier 1 supplier facilities, 29% participate in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program, which is a program designed to address pharmaceutical and medical device supply chain security in relation to public health concerns and patient safety. Through both 3rd-party and our own supplier audits, we are able to remain confident in our suppliers' ability to maintain GMP, resulting in the production of safe and effective products.

Supplier Training and Upholding Standards

To ensure suppliers are equipped with the appropriate resources and knowledge to secure a safe workplace that produces quality products, Catalyst provides suppliers with various types of training. One hundred percent of supply chain partners for post product release are required to complete specialized training. Catalyst provides adverse event and product complaint report training to staff at our patient services vendor, distributor/3PL (third-party logistics) provider, and primary specialty pharmacy vendors for released product. In addition, when initiating a clinical trial, all investigators and staff are trained on the requirements for reporting adverse events and product complaints.

Counterfeit Drugs

Catalyst understands that counterfeit drugs pose both a major public health concern and reputational risk to our Company. To minimize that risk and protect the safety of our patients, we comply with all statutes and regulations related to serialization of product, traceability, and counterfeit prevention of pharmaceutical products. These procedures ensure we are able to uphold our values of integrity and commitment to the highest ethical standards.

Catalyst is a member of GS1, an organization that sets standards for unique product identifiers. These standards are necessary for effective international track and trace functionality pertaining to serialized prescription drugs. GS1 product serialization standards efforts allow for clear identification of the source of serialized pharmaceutical products to prevent counterfeiting and diversion. Through our membership with this organization, Catalyst remains at the forefront of industry developments and best practices related to managing the risk of counterfeit drugs.

To facilitate product identification and movement from product release to dispense to patients, Catalyst tracks serial numbers throughout the distribution channel. Our TraceLink system is responsible for generating and managing serialization of our products down to the individual package level. Each package unit and aggregate package unit including the carton, case, and pallet is affixed with a barcode that details its serial number. Through our restricted distribution system in the U.S and our product serialization system, Catalyst is able to identify the recipients of all products we manufacture and distribute. Due to our strong methods and technologies to prevent counterfeit drugs, Catalyst did not have any incidents related to counterfeit drugs in 2022. With that said, in the event of suspect product reports, our internal policy specifically outlines the steps Catalyst employees and management should take to notify patients, business partners, and the FDA if a product is determined to be counterfeit or illegitimate. In the event Catalyst needs to issue a recall, we would disclose this occurrence per our standard disclosure requirements up to and including initiating a recall. This would be based on our Standard Operating Procedure describing how to determine when to initiate a recall and all subsequent activities until the recall has been terminated.

Human Rights

Catalyst is committed to protecting human rights at our Company and throughout the supply chain. Catalyst does not tolerate child labor, forced labor, or other breaches of human rights. We are confident that we have the appropriate mechanisms and policies in place to prevent human rights incidents and ensure any incidents would be reported and addressed immediately. As a result of our commitment to ensuring a safe working environment, Catalyst and Catalyst suppliers did not identify or report any human rights violations in 2022.



Access to Healthcare

Catalyst is committed to providing its product available to all patients regardless of their ability to pay.

Access to Medicines

Catalyst is committed to ensuring all patients have access to FIRDAPSE®, regardless of their ability to pay, thus aligning with our unwavering commitment to the patient community that we serve. In doing so, we provide patients with accessibility programs, such as Catalyst Pathways®, which is a patient services program that offers a suite of financial and education resources to help patients and their caregivers, and through expanded access programs.

Catalyst Pathways® is a free, comprehensive patient service offering patients and families support throughout their treatment journey. Through this program, we seek to help ensure that all patients have the opportunity to receive access to our medicine for the treatment of their LEMS by providing personalized support through a dedicated team of specialists that can help manage their unique challenges. Catalyst Pathways® programs offer an array of patient and financial services, including educational resources, insurance information, and support identifying financial assistance program eligibility.

Catalyst Pathways® also includes a delivery assurance program in which Catalyst team members monitor, anticipate, and plan for potential drug delivery obstacles to ensure patients have uninterrupted access to their medication. The Catalyst Pathways® program underscores our commitment to our patients to ensure each individual receives the support they need.

Catalyst PATHWAYS®

Catalyst supports the distribution of FIRDAPSE® in the United States through Catalyst Pathways®, our personalized treatment support program. Catalyst Pathways® provides enrolled patients with personalized treatment support, education, and guidance, supporting them through challenging dosing and titration regimens required to reach an effective therapeutic dose. Catalyst Pathways® also works with a small group of exclusive specialty pharmacies that dispense FIRDAPSE®, primarily AnovoRx Specialty Pharmacy. The low volume of distribution and limited patient base – most of whom Catalyst is in contact with through the Catalyst Pathways® program – alongside our recommendation that purchases only be made from recognized and approved vendors within that small supply chain significantly decreases the risk of counterfeit products.

CONNECT WITH OUR TEAM OF CARE COORDINATORS AND PATIENT ACCESS LIAISONS ("PALS") TO UNDERSTAND YOUR MEDICATION AND FIND THE RESOURCES AND HELP YOU NEED. PLEASE FOLLOW THE LINK TO THE YOUR DEDICATED TEAM WEBPAGE.

Visit the Catalyst Pathways® Financial Assistance webpage to learn more about the programs available to keep treatment affordable:

Catalyst Copay Assistance: For patients with commercial insurance, Catalyst Pathways® lowers out-of-pocket costs to below $10/month. While patients with government insurance may have a higher copay, most qualify for Third-Party Foundation Assistance.

Third-Party Foundation Assistance: If a patient is having trouble paying their out-of-pocket costs, Catalyst Pathways® can inform them of nonprofit organizations that can help them pay for their medicine. If they have Medicare coverage and qualify for Foundation Assistance, their copay may be $10 or less.* Call Catalyst Pathways® at 1-833-422-8259 for further information.

Patient Assistance Program ("PAP"): If a patient does not have insurance or is denied coverage, Catalyst Pathways® provides free medicine to those who qualify.

Pat: "Within a week after receiving FIRDAPSE® I got a call from my Catalyst Pathways® Patient Access Liaison to check on how the medication was working for me. She was so encouraging and supportive. She also set up an in-person visit to help us navigate all of my concerns and provide information about FIRDAPSE® and Catalyst. From that day forward the support from Catalyst has been amazing! I know there is always someone to contact for anything I need."

Andrea: "I always look forward to helping our patients. As a Patient Access Liaison, each interaction gives me an opportunity to not only educate and answer any questions about their diagnosis, but I also get to know each of my patients. I feel patients need to know they are not a number at Catalyst but a person and will be treated as such."

Additional Efforts to Optimize Coverage and Access

Catalyst actively works with insurance companies to optimize coverage for our U.S. approved products including developing a support program for privately insured patients in need. For those patients who may be underinsured or uninsured and who meet financial need qualifications, we provide our product free of charge through the Patient Assistance Program ("PAP"). Catalyst patients with commercial coverage are also eligible for a co-pay assistance program designed to keep out-of-pocket costs for FIRDAPSE® to less than 10 dollars per month.

Compassionate Use

Through FDA's Compassionate Use programs, patients in the United States may gain access to our product at no charge prior to FDA approval after a request from their physician. Catalyst currently makes medicine available to a limited number of patients diagnosed with Congenital Myasthenic Syndrome, MuSK positive myasthenia gravis, and Downbeat Nystagmus. Refer to our website for more information about Catalyst's Compassionate Use process.

Supporting Generic Alternatives

Catalyst also recognizes the societal value in the development of generic alternatives to branded medications, subject to FDA exclusivities and existing patent protections. Catalyst is cooperative in supplying sample material to generic competitors, upon appropriate requests, to allow for the formulations of generic alternatives.

Affordability and Pricing

At Catalyst, we believe that all patients should have access to affordable medicine. Through our pricing strategies, we ensure Catalyst medication is appropriately priced and support systems are available to increase affordability and accessibility to all patients, especially those who could otherwise not afford the medication. Our commitment to equitable and consistent pricing is demonstrated by minimal changes in the pricing of our products year over year.

Our Employees

At Catalyst, we believe that our employees are our most valuable asset who serve as the primary drivers of our Company's long-term growth and success. Thus, efforts to attract, support, train, communicate with, and retain our employees are central to executing our ESG strategy and supporting Company-wide growth. We strive to foster a safe, open, diverse, and growth-oriented working environment for our employees to thrive. Our Company is dedicated to continuously investing in our employees through engagement programs as well as protecting our employees' health, safety, and well-being.

Employee Recruitment, Development, & Retention

Workforce Overview

Our workforce is comprised of individuals supporting commercial, research and development ("R&D"), and general & administrative areas ("G&A"). The demographic emphasis on R&D and commercialization directly supports our mission to provide novel therapeutics to treat rare diseases for our patients.

Based on data from 2022 10-K, calculated on 3/15/2023.

Workforce Development

We strive to create a supportive work environment that provides professional growth and development opportunities to every employee. In 2022, we instituted a tuition reimbursement program to provide support for employees pursuing accredited degree or certification programs. We are proud to support the Catalyst employees that are working towards new degrees as part of the program.

Additionally, we support employees seeking career development through continuing education training such as Continuing Medical Education ("CME"), Clinical Professional Education ("CPE"), Continuing Legal Education ("CLE"), and other job-specific certifications and training.

Employee Training

Catalyst takes an operational approach to employee training, with all new hires receiving onboarding training that covers pertinent Company policies and procedures relevant to position-specific skills. To ensure expectations are frequently communicated to employees, Catalyst provides refresher courses on Company policies, such as the Code of Ethics and Anti-harassment. We believe this training approach is best suited for our employees' needs and ensures all employees are well equipped to perform their job responsibilities.

Talent Attraction & Retention

Catalyst is committed to attracting, retaining, and developing high-quality talent across the industry. Our approach to recruitment and retention is uniform across all roles and activities within the Company, though occasionally, individual hiring needs may be prioritized based on the needs of the business. As we grow, we will continue to adapt and scale our talent attraction strategy with an increased focus on attracting commercialization professionals. In an effort to attract employees that share our beliefs and mesh with the Catalyst culture, we leverage both our internal professional networks and alternate external methods. We demonstrate our appreciation for employee contributions by awarding all new hires with stock options, providing employees with a tangible share in our future success. Through our workforce development, training, compensation and benefits packages, and employee satisfaction programs, we strive to promote a work environment that minimizes workforce attrition. In 2022, we experienced 13.3% in employee turnover, a flat year-over-year change from 2021.

IN 2022, WE HIRED 10 NEW EMPLOYEES TO SUPPORT OUR STRATEGIC GROWTH PLANS.

Employee Engagement & Satisfaction

In order to attract and retain high-quality professionals with the experience and expertise to further our mission and strategic growth plans, we prioritize a high employee satisfaction rate and create an environment where employees can thrive and grow in their careers, while feeling safe and valued. With this commitment, we often engage our employees and seek their feedback to improve our culture continuously.

Catalyst conducts an annual employee survey which consists of engagement on critical workforce topics resulting in greater transparency for our organization:

- Management practices;
- Employee trust;
- Company policies;
- Pandemic performance; and
- Company communications.

Catalyst employees receive annual performance reviews to gain feedback on continued professional development and organic growth with our Company. We also offer optional mid-year reviews, and in 2022, more than 90% of employees participated. Through our efforts, our average workforce tenure is 4.1 years.



Employee Benefits and Incentives

We review our incentive structures regularly to determine if they are adequately aligned with Company strategy and that these are attractive and compelling based on current market conditions. We offer a comprehensive package of benefits, including a 401K with safe harbor match and a stock incentive plan for all eligible employees.

Compensation packages for all employees include:

- Market competitive base salaries;
- Annual performance bonuses; and
- Stock option grants.

Our benefits programs include:

- Company sponsored medical, dental and vision health care coverage;
- Life and AD&D insurance;
- 401(k) plan with a matching employer contribution;
- Employee assistance program; and
- Tuition reimbursement program.

Employee Health & Safety

At Catalyst, we are committed to providing each employee with a safe work environment. Catalyst employees must follow corporate health and safety practices and report any accidents, injuries, or unsafe equipment, practices, and conditions. Additionally, Catalyst personnel are required to understand and comply with the Code of Business Conductand Ethics as outlined in our Business Ethics & Transparency section. Due to our scope of operational activities and corporate based operations – office-based or field pharmaceutical support – hazardous activity has been assessed as a low risk for Catalyst. Catalyst reported zero worker injuries or work-related illnesses in 2021 and 2022.

Diversity, Equity, & Inclusion

As part of our mission to incorporate diversity, equity & inclusion into our business and harness the potential of our employees, we continue to cultivate and foster a workplace the recognizes our commitment to mutual respect and acceptance. We are committed to a culture of inclusivity and belonging across all areas of our Company, which is an integral part of our core values.

We actively take diversity into account when evaluating candidates for open positions and ensure the hiring process is fair and equitable across our organization. We foster an atmosphere that promotes equal opportunities and prohibits discriminatory practices, prejudice, and harassment of any kind.

Our commitment to an inclusive culture is represented by the diverse demographics our of workforce. Specifically, 44% of our workforce and 44% of senior management are represented by minority groups.

Our comprehensive diversity, equity, inclusion metrics including gender and ethnicity and race data, across our entire organization, are displayed in our Performance Data table. Looking forward, we will continue to report these metrics publicly.



IN 2022, OVER 90% OF EMPLOYEES REPORTED BEING SATISFIED TO VERY SATISFIED WITH THEIR EXPERIENCE AT CATALYST.

Community Involvement

At Catalyst, we are dedicated to giving back to the communities which are connected to our business as well as continuously supporting our rare disease patient community that needs treatment and care for LEMS.

Through working closely with the communities in which we can be a force of change, we continue to find opportunities for meaningful community engagement and contributions to a more equitable society. Notably, Catalyst has been a long-time supporter of various charities through donations and employee volunteer efforts:

- We have partnered with **Medical Students in Action** to support medical students from the University of Miami Miller School of Medicine to travel to regions with urgent healthcare needs.
- Catalyst is also working with the **Camillus House**, which provides humanitarian services to the impoverished and homeless populations of Miami-Dade County in Florida.
- Catalyst donated to the **Woody Foundation**, a non-profit organization in Florida, to support efforts to transform the quality of life of those living with paralysis and their caregivers.

In 2022, we supported 7 organizations within our local and medical communities.

MEDICAL STUDENTS IN ACTION

THE WOODY FOUNDATION

CAMILLUS HOUSE & HEALTH

Supporting Communities in Access to Healthcare

At Catalyst, we care deeply about the patient community with which we interact. We believe that every patient should have access to necessary medication, and we are committed to making our products available to all patients regardless of their identities and financial abilities. Our goal has always been that no LEMS patient is ever denied access to their medication for financial reasons.

We have multiple access to healthcare and patient services programs through Catalyst Pathways® and additional efforts which help provide our patients and their caregivers with financial and educational resources, and expanded access to FIRDAPSE®. Details on these programs can be found in our Access to Healthcare section.

Additionally, we have dedicated positions within our workforce focused on improving our patient community's access to healthcare including our National Account Managers, who have extensive knowledge with payors, work to ensure that FIRDAPSE® is covered by most commercial and governmental plans in the United States. We also have a field force of five Medical Science Liaisons that support LEMS education and our ongoing clinical trial activities among medical communities.

From a community involvement perspective, we have been donating money to qualified, independent charitable foundations dedicated to assisting any LEMS patients in the United States who are in financial need. In addition to our active efforts to ensure our patient community has access to medicine, we also work to educate misdiagnosed and undiagnosed LEMS patients. With a focus on expanding awareness and understanding of LEMS, we provide educational activities to help improve diagnosis, treatment understanding, and prescription process information. In support of this, we collaborate with several rare disease advocacy groups to raise awareness and knowledge of patients living with LEMS to help patients understand the differences between LEMS and other neuromuscular diseases often misdiagnosed instead of LEMS. Some of the organizations we are working with on these important efforts include:

- Global Genes;
- The National Organization for Rare Disorders;
- The Mighty; and
- The Myasthenia Gravis Foundation of America.

Patient Engagement Team

Our patient engagement team leads external communications with advocacy organizations and serves as Catalyst's community voice champion. Throughout all engagements, we keep community feedback and insights top-of-mind. The mission of our patient engagement team is simple: to build and sustain trusting relationships with families and advocacy organizations in order to address rare disease issues and create opportunities to make a difference in patients' lives.

GUIDING PRINCIPLES

As outlined in our Patient Engagement Charter, to ensure that our relationships with patients and patient organizations are thoughtful and transparent, we rely on the following principles:

- We recognize and respect the autonomy of our advocacy partners and seek to reinforce their independence and integrity. We will not place our interests above theirs.
- We will not request or expect a patient organization to promote a Catalyst Pharmaceuticals product.
- We will be open and transparent about the objectives and scopes of any collaboration with patient organizations.
- We will respect and guard the privacy of all personal information and data we may receive from patients and patient organizations. We will only release information if given consent.
- We strongly encourage patient organizations to pursue and establish multiple funding sources.
- We will acknowledge Catalyst's support and sponsorships of such organizations.

As we continue to support patient advocacy groups and initiatives that improve the lives of those suffering from rare neuromuscular diseases, a formal process to review charitable requests has been established to identify and support requests from qualified non-profit organizations related to the patient communities we serve. **For more information and application requirements, please email our Patient Engagement team at PatientEngagement@catalystpharma.com.**

Investigator-Sponsored Research

Beyond patient engagement we are also committed to advancing the knowledge necessary to address the unmet needs of patients with rare diseases. We participate in investigator-sponsored research ("ISR") to generate promising medical interventions. Specifically, ISR comprises clinical studies that are initiated and managed by non-pharmaceutical company researchers, such as individual investigators, institutions, collaborative study groups, and cooperative groups.

More detail on our ISR requirements and how to submit a proposal can be found on our Investigator-Sponsored Research webpage. Additionally, for further questions about the process, or to discuss specific proposals, please contact us at: **isr@catalystpharma.com**.

ENVIRONMENT

Environment

At Catalyst, we recognize the importance of supporting a sustainable future for our world and that climate protection requires global action. While our environmental impact is minimal compared to many companies due to our size, low volume, and small focus, we are committed to establishing positive impact within our organization and across the value chain in which we operate. As outlined in our Environmental Strategy section, we are committed to initiating actionable steps to improve our environmental program, reporting, and transparency for all stakeholders.

Environmental Strategy

Our Corporate Responsibility Steering Committee was established in 2021 to oversee and evaluate Catalyst's current status on ESG issues, set goals, and to develop policies, strategies, and metrics to support those goals.

With the foundation of this committee, we are positioned to develop appropriate environmental strategies and program objectives. Aligned our broader ESG oversight strategy, environmental matters are also overseen by the entire Board (refer to the ESG Oversight section for further details).

AS WE EVALUATE THE UTILITY TO OUR BUSINESS AND THE EVOLVING REGULATORY LANDSCAPES, WE WILL ADDRESS THE FOLLOWING ENVIRONMENTAL CONSIDERATIONS:

Identify the climate-related risks and opportunities within our organization and value chain.

Work towards measuring and reporting available information on our Scope 1 and 2 emission footprints, unlocking our ability to set measurable emissions reduction targets.

Enhance our ESG reporting with alignment to dedicated environmental 3rd party frameworks, such as the Task Force on Climate-related Disclosures ("TCFD").

Catalyst's only location of operation, our 12,000 square foot corporate office is located in a LEED silver certified green building. The building, including our office, has been designed, constructed, and operated in a way that **promotes sustainable practices by increasing energy efficiency, practicing water conservation, and minimizing waste with recycling efforts.** To that end, Catalyst operates with a **relatively low environmental footprint.**



Emissions & Energy Management

Catalyst is beginning to implement a formal process to measure and monitor our greenhouse gas ("GHG") emissions and energy consumption. Given our relatively smaller organizational footprint and low volume manufacturing, we estimate our largest source of emissions and energy footprint comes from our day-to-day activities and maintenance in our corporate office, as well employee travel. To conserve energy, our corporate office has implemented various technologies, such as occupancy sensors on lighting, energy efficient lighting, and CO_2 sensors on air conditioning equipment to maximize fresh air intake while reducing the need to cool non-essential outside air.

Additionally, since March 2020, Catalyst has implemented a hybrid working model that enables many employees to regularly work from home. Working from home directly reduces our employees' emissions footprint through reduced commuting and use of our corporate office facilities. Aligned with our environmental strategy, we will continue to improve the scope of our emissions and energy disclosure in future reporting cycles to provide transparency to our stakeholders and catalyze our go-forward environmental strategy.

Waste & Water Management

Although Catalyst leases our corporate office, we are dedicated to developing a better understanding of our waste generation and water consumption in order to expand our sustainable initiatives.

Given that the majority of our activities are executed electronically, we generate relatively little paper waste from our operations. Catalyst supports the waste management and recycling policies initiated by the LEED-certified building, which includes a comprehensive recycling program that collects office paper, cardboard, plastic, glass, lightbulbs, and batteries. By doing this, 95% of the building's waste is diverted from landfills.

Catalyst also offers a program that enables employees to acquire obsolete electronics for personal use, such as laptops, iPads, and printers, to divert from waste and eliminate the need to dispose of materials which can potentially be harmful to the environment.

Similarly, Catalyst's own water consumption is minimal as our sole direct use of water is to support the operation of our Corporate office. As a LEED certified building, our corporate office has various measures in place to reduce water consumption, such as sink aerators and low flow fixtures in bathrooms and rain gauge moisture sensors on landscaping irrigation systems.

Supply Chain Engagement

Given our smaller operational footprint, we expect a larger proportion of our carbon footprint lies in our Scope 3 emissions, directly associated with our suppliers and vendors. As we continue to develop our environmental program, we are engaging with our suppliers on ESG issues, including those dedicated to the environment. Looking forward, we are excited for the opportunities to collaborate with our suppliers and across our value chain to improve our collective environmental footprint.

GOVERNANCE

Corporate Governance

Catalyst believes sound corporate governance is implicit in setting high standards for the Company's employees, Officers, and Directors. Our governance policies and personnel reinforce Catalyst's values in every aspect of business conduct. We believe corporate governance, with ESG as a critical component, is the natural substructure for delivering on long-term sustainable value creation for our share-holders and all stakeholders.

Board Composition

The Board of Directors serves as a prudent fiduciary for shareholders and is responsible for the oversight of Catalyst's business management. Catalyst requires members of the Board of Directors to also uphold our key values of passion, trust, and integrity. Our Board of Directors is subject to guidelines outlined in our Code of Business Conduct and Ethics and respective committee charters to ensure all decisions are made in the best interests of the Company.

Our Board of Directors is currently comprised of seven members, each of whom serve on various committees. The diversity of expertise and backgrounds on our Board positions us well to make decisions that maximize both our market position and our ability to develop innovative solutions for rare diseases. The Board leadership structure is reviewed regularly to ensure members continue to be able to make strong decisions against the evolving business landscape.

Patrick J. McEnany

Chairman,
Chief Executive Officer
Independence: -
Audit: -
Compensation: -
Nominating & Corporate Governance: -

Relevant Experience

Jackson Memorial Hospital Foundation
National Association of Pharmaceutical Manufacturers
Royce Laboratories, Inc.
Watson Pharmaceuticals, Inc.

Philip H. Coelho

Independence: **Yes**
Audit: **Member**
Compensation: -
Nominating & Corporate Governance: **Member**

Relevant Experience

Trenchant Biosystems, Inc.
SynGen, Inc.
Thermogenesis Corp.
Ampio Pharmaceuticals, Inc.

Richard J. Daly

Independence: **Yes**
Audit: -
Compensation: **Member**
Nominating & Corporate Governance: **Member**

Relevant Experience

AstraZeneca PLC
BeyondSpring, Inc.
CARsgen Therapeutics Holdings Ltd.
Neuralstem, Inc.
Opiant Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc.

Donald A. Denkhaus

Independence: **Yes**
Audit: **Member**
Compensation: -
Nominating & Corporate Governance: **Member**

Relevant Experience

Arthur Andersen LLP
Noven Pharmaceuticals, Inc.
Nuovo Biologics, LLC
The Kitchen, LLC

Molly Harper

Independence: **Yes**
Audit: -
Compensation: **Member**
Nominating & Corporate Governance: **Member**

Relevant Experience

Akcea Therapeutics, Inc.
PreciseDx
Relmada Therapeutics, Inc.
Sanofi Genzyme
Synlogic, Inc.
Merck & Co., Inc.
UBS

Charles B. O'Keeffe

Lead Independent Director
Independence: **Lead Director**
Audit: **Member**
Compensation: **Member**
Nominating & Corporate Governance: **Member**

Relevant Experience

Pharmaceutical Services, Inc.
Reckitt Benckiser Pharmaceuticals, Inc.
UN Commission on Narcotic Drugs
Virginia Commonwealth University School of Medicine
Washington Reference Laboratories
White House Advisor
World Health Assembly

David S. Tierney, M.D.

Independence: **Yes**
Audit: -
Compensation: **Member**
Nominating & Corporate Governance: **Member**

Relevant Experience

Aramis Biosciences, Inc.
Bimeda, Inc.
BioPharmX Corp.
Biovail Technologies Ltd.
Icon Bioscience, Inc.
Zevra Therapeutics, Inc.
Oceana Therapeutics, Inc.
Pharma Two B Ltd.
Valera Pharmaceuticals, Inc.

We have no established term limits or mandatory retirement policies for our Board members as our refreshment protocols are effective and those with greater tenure often offer greater insight and perspective related to the objectives in focus.

Various committees support our Board of Directors, with the responsibilities of each detailed in our committee charters:

Compensation Committee
The Compensation Committee is responsible for decisions related to compensation of the Company's executives, recommending and approving compensation plans for Company employees, and producing an annual report on executive compensation.

Audit Committee
The Audit Committee oversees the accounting and integrity of financial reporting, compliance with legal and regulatory requirements, performance of the Company's internal audit function, and audits of the Company's financial statements, including appointment of independent auditors. Responsibilities of the Committee include messages to stockholders, developing risk management structures, and ensuring legal, ethical, and regulatory compliance.

Nominating and Corporate Governance Committee
The Nominating and Corporate Governance Committee assists the Board in identification and selection of qualified Board member candidates, development and recommendation of corporate governance guidelines, and oversight of evaluation of the Board.

To ensure business matters are discussed and handled in a timely manner, each committee of the Board conducts regular meetings, with a full Board meeting held at least quarterly. While Board members are not required to attend each meeting, we are proud to note that over the past year, all Board members attended all ten Board meetings. In addition, all committee meetings in 2022 were attended by all committee members. High attendance at each meeting demonstrates the Board's commitment to ensuring Catalyst's success and ensuring intimate familiarity with pertinent business and regulatory matters.

Executive Incentives

Catalyst seeks to attract individuals who can execute on our mission in a manner that creates value for our shareholders and other key stakeholders. We seek to balance near-term financial and operational performance with long-term success. As stated in our 2022 Proxy Statement, we structure our compensation plans to provide incentives for long-term value creation. Using a mix of base pay, bonus compensation, and additional long term incentive compensation, we are able to offer a competitive package to attract, retain, and motivate critical personnel to meet or exceed our goals.

Oversight of executive compensation is appointed to the Compensation Committee. The Compensation Committee meets regularly to ensure they make informed decisions on executive compensation using fair payment practices that align with Catalyst's long term strategic goals. In evaluating executive compensation, the Compensation Committee receives third-party data and analysis on market trends and competitive practices from an independent compensation consultant to ensure pay practices are competitive relative to industry standards and are equitable and reasonable.

Shareholder Rights

Catalyst values input from our shareholders and engages with shareholders frequently. Catalyst's Annual Meeting of Stockholders provides a forum for opinions to be voiced and proposals discussed and voted upon. Each holder of common stock is entitled to one vote on all matters on which stockholders generally are entitled to vote including the election of Board members, which occurs annually. Additionally, as part of the Annual Meeting process, the Annual Report and Proxy Statement are provided to update all on business matters.

Going forward, we will continue to solicit opinions and proactively engage with stockholders and key stakeholders to ensure all formal and informal proposals are considered as long as they reasonably enhance value creation and strengthen Catalyst's ability to serve patients.

Risk Management

Strong and cross-functional risk management is essential to protect Catalyst's patients, employees, shareholders and business strategy. Our risk management processes are supported by the appropriate systems and personnel to identify, assess, and mitigate risks, making our business resilient and agile to the ever-changing business environment in which we operate.

Risk Oversight

Risk oversight is administered through the Board of Directors as a whole and is supported and implemented by Committees of the Board, senior executives, and cross-functional operations managers. Each party has various responsibilities associated with addressing risks and regulatory requirements to facilitate Catalyst's long-term success and sustainability for all stakeholders.

Risk Management Responsibilities

BOARD OF DIRECTORS

Risk Oversight

- Review risk assessment and create risk management plans based on identified risks.
- Address risk management concerns, including mitigation and remediation plans.
- Oversight of the Company's internal audit function, including internal controls over financial reporting, to preserve the integrity of financial statements.
- Appoint, compensate, retain, and oversee the work of independent auditors.

SENIOR EXECUTIVES (C-Suite and Vice Presidents)

Risk Oversight Strategy Implementation

- Ensure risk management policies and procedures determined by the Board of Directors in conjunction with independent auditors are implemented.
- Serve as a bridge for communication between managers and the Board of Directors.

MANAGERS & INDIVIDUAL CONTRIBUTORS

Day to Day Risk Management Activities

- Day to day risk management based on job duties including facilitation of internal controls.
- Identification and escalation of any potential operational barriers in implementing internal controls and communicating status to executives.

INDEPENDENT AUDITOR

- Perform audit of the Company's annual financial statements, expressing an opinion as to the conformity of such annual financial statements with generally accepted accounting principles.
- Review over Company's quarterly financial statements to ensure regulatory compliance.
- Report findings to the Audit Committee of the Board of Directors.

Catalyst has internal controls in place to address financial, operational, and regulatory risks. These internal controls have been developed specifically to ensure financial statements are prepared accurately and in accordance with applicable regulations. The Audit Committee, supported by an independent auditor, is responsible for ensuring internal controls are properly implemented, monitored, and remediated, if necessary. The Audit Committee and management communicate regularly to discuss progress made throughout the Company from a risk management perspective. This line of communication promotes accountability and ensures Catalyst is able to respond timely to identified risks.

In addition to its ongoing analysis of risk, Catalyst performs a risk assessment, as highlighted annually in the development of our Form 10-K to identify risk factors that have potential to materially impact our business. Conducting a risk assessment ensures we have a clear understanding of the risks and opportunities impacting our Company. By identifying risks, we are putting ourselves in a better position to formulate risk mitigation plans

Regulatory Preparedness

The FDA has rigorous regulations pertaining to the development, release, and manufacturing of drugs. To ensure we are meeting all FDA regulations, we follow good laboratory practice (GLC) during pre-clinical drug development, good clinical practices (GCP) during clinical trials, and good manufacturing practices (GMP) during the manufacturing stage of our products. We are confident in our ability to adhere to regulations and therefore welcome FDA inspections and further studies. By following these procedures, we are able to complete well-controlled clinical trials and consistently produce safe and effective products for our patients because compliance with these regulations is top of mind and failure to comply with regulations may affect patients in addition to impacting our product in the marketplace.

Data Privacy and Security

Cyber breaches and data security concerns are risks identified in Catalyst's annual risk assessment. Our data protection policies and infrastructure ensure patient and provider information remains protected and confidential, which is key in maintaining regulatory compliance and patient trust. As outlined in our Code of Business Conduct and Ethics, all Catalyst personnel have an obligation to protect Company assets and propriety information.

In addition, our Privacy Policy outlines the steps we take to protect personal information from loss, misuse, alteration, or destruction. Unauthorized use or distribution of information maintained by Catalyst is prohibited and all Catalyst personnel are required to maintain confidentiality of material non-public information. We will continue to monitor best practices regarding data security and update our policies and procedures, when needed, to adapt to changes in the digital environment and secure both patient and Company information.



Indexes & Performance Data

Performance Data

GENERAL DATA

Metric	Unit of Measure	FY 2021	FY 2022
Revenue	Dollars ($)	$140,833,000.00	$214,203,000.00
Total Employees[1]	Number	75.5	75.0
Full-Time Employees[2]	Number	73.5	73.0
Part-Time Employees[3]	Number	2.0	2.0
Contracted Workers[4]	Number	0.0	0.0
Average Executives Employee Headcount[5]	Number	10.0	9.5
Average Mid Level Managers Employee Headcount[5]	Number	12.5	15.5
Average Professionals Employee Headcount[5]	Number	34.5	31.0
Average Sales Employee Headcount[5]	Number	16.0	16.0
Average Administrative Employee Headcount[5]	Number	2.5	3.5

SOCIAL DATA

Metric	Unit of Measure	FY 2021	FY 2022
Our Employees			
Talent Attraction			
New Hires	Number	–	10.0
Average Employee Length of Service[6]	Years	–	4.1 years
Voluntary Turnover Rate[5]			
Voluntary Turnover Rate All Employees	Percentage (%)	9.3%	10.6%
Voluntary Turnover Rate Executives	Percentage (%)	0.0%	10.5%
Voluntary Turnover Rate Mid Level Managers	Percentage (%)	8.0%	6.5%
Voluntary Turnover Rate Professionals	Percentage (%)	5.8%	19.4%
Voluntary Turnover Rate Sales	Percentage (%)	18.8%	0.0%
Voluntary Turnover Rate Administrative	Percentage (%)	40.0%	0.0%
Voluntary Turnover Rate All Employees	Number	7.0	8.0
Voluntary Turnover Rate Executives	Number	0.0	1.0
Voluntary Turnover Rate Mid Level Managers	Number	1.0	1.0
Voluntary Turnover Rate Professionals	Number	2.0	6.0
Voluntary Turnover Rate Sales	Number	3.0	0.0
Voluntary Turnover Rate Administrative	Number	1.0	0.0
Involuntary Turnover Rate[5]			
Involuntary Turnover Rate All Employees	Percentage (%)	4.0%	2.7%
Involuntary Turnover Rate Executives	Percentage (%)	0.0%	0.0%
Involuntary Turnover Rate Mid Level Managers	Percentage (%)	8.0%	0.0%
Involuntary Turnover Rate Professionals	Percentage (%)	2.9%	6.5%
Involuntary Turnover Rate Sales	Percentage (%)	6.3%	0.0%
Involuntary Turnover Rate Administrative	Percentage (%)	0.0%	0.0%
Involuntary Turnover Rate All Employees	Number	3.0	2.0
Involuntary Turnover Rate Executives	Number	0.0	0.0
Involuntary Turnover Rate Mid Level Managers	Number	1.0	0.0
Involuntary Turnover Rate Professionals	Number	1.0	2.0
Involuntary Turnover Rate Sales	Number	1.0	0.0
Involuntary Turnover Rate Administrative	Number	0.0	0.0
Diversity and Inclusion			
Incidents of Discrimination	Number	0.0	0.0
Gender			
Women representation of employees[7]	Percentage (%)	57.0%	61.0%
Men representation of employees	Percentage (%)	43.0%	39.0%
Not disclosed (all employees)	Percentage (%)	0.0%	0.0%
Women representation in senior management positions[8]	Percentage (%)	30.0%	33.0%
Men representation in senior management positions[8]	Percentage (%)	70.0%	67.0%
Race/Ethnicity (all employees)			
Total employees represented by minority groups	Percentage (%)	40.0%	44.0%
White	Percentage (%)	60.0%	56.0%
Asian	Percentage (%)	9.3%	10.5%
Hispanic/Latino	Percentage (%)	25.3%	26.3%
Black or African American	Percentage (%)	4.0%	6.6%
Other Ethnicities[9]	Percentage (%)	1.3%	1.3%
Not disclosed	Percentage (%)	0.0%	0.0%
Race/Ethnicity (senior management)			
Senior management represented by minority groups[8]	Percentage (%)	40.0%	44.0%
White	Percentage (%)	60.0%	56.0%
Asian	Percentage (%)	30.0%	33.0%
Hispanic/Latino	Percentage (%)	10.0%	11.0%
Black or African American	Percentage (%)	0.0%	0.0%
Other Ethnicities[9]	Percentage (%)	0.0%	0.0%
Not disclosed	Percentage (%)	0.0%	0.0%
Human Rights			
Incidents of Violations Involving Rights of Indigenous Peoples	Number	0.0	0.0
Operations at Risk for Child Labor[10]	Number/Percentage (%)	0.0%	0.0%

1 *Accounted for on 12/31/2022 based on employee average headcount for full-time and part-time employees throughout fiscal year 2022.*
2 *Accounted for on 12/31/2022 based on employee average headcount for employees who worked 40 hours per week throughout fiscal year 2022.*
3 *Accounted for on 12/31/2022 based on employee average headcount for employees who worked less than 40 hours per week throughout fiscal year 2022.*
4 *Accounted for on 12/31/2022 based on employee average headcount for employee types consultant or contractor throughout fiscal year 2022.*
5 *All employees classified according to the U.S Equal Employment Opportunity Commission EEO-1 Job Classification Guide.*
6 *Average across all Catalyst employees.*
7 *Calculations based on fiscal years ending 12/31/21 and 12/31/22*
8 *Senior Management refers to Executives and Senior Managers.*
9 *Includes two or more races, American Indian or Alaska Native, and Native Hawaiian or Pacific Islander*
10 *Based on assessment of all operating Catalyst facilities.*

SOCIAL DATA, CONTINUED

Metric	FY 2021	FY 2022
Employee Training and Development		
Required Employees who Complete Code of Conduct Training[11]	–	100.0%
Employees Receiving Regular Performance Reviews[12]	–	100.0%
Health and Safety		
Work-related Injuries	0.0	0.0
Work-related Ill Health	0.0	0.0
Patients and Product		
Patients Treated[13]	>1,000	>1,000
Drugs in Portfolio	1.0	1.0
Drugs in Research and Development	1.0	1.0
Products Assessed for Safety[14]	100.0%	100.0%
Recalls issued	0.0	0.0
Year over year FIRDAPSE Price Change	<5.0%	<5.0%
FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP)	0.0	0.0
FDA Sponsor Inspections resulting in Voluntary Action Indicated (VAI)	0.0	0.0
FDA Sponsor Inspvections resulting in Official Action Indicated (OAI)	0.0	0.0
Total monetary losses as a result of legal proceedings associated with clinical trials in developing countries	0.0	0.0
Settlements of ANDA litigation that involved payments and/or provisions to delay bringing an authorized generic product to market	0.0	0.0
Fatalities associated with products reported in the FDA Adverse Event Reporting System[15]	33.0	29.0
Actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	0.0	0.0
Communities		
Philanthropy		
Charitable Donations[16]	–	$5,092,500.00

11 *Training for this topic was assigned to all Catalyst employees.*
12 *Performance reviews conducted at least annually for all Catalyst employees.*
13 *From launch in January 2019 through FY 2022.*
14 *Subject to quality testing prior to patient use.*
15 *Fatalities from patients taking FIRDAPSE. Note, there is a high prevalence of cancer and autoimmune comorbidities present in LEMS patients, and no fatalities can be directly attributed to FIRDAPSE use.*
16 *Charitable contributions to 501(c)(3) organizations for patient support, patient advocacy, and medication education.*

GOVERNANCE DATA

Metric	Unit of Measure	FY 2021	FY 2022
Board Composition			
Board Members	Number	7.0	7.0
Board Member Average Term Duration	Years	12.3	13.3
Board of Directors Average Age	Years	67.6	68.6
Board of Directors Gender Representation	Percentage (%)	14.3%	14.3%
Independent Directors	Number	6.0	6.0
Board Member Diversity			
Female Board Members	Number	1.0	1.0
Male Board Members	Number	6.0	6.0
White	Number	6.0	6.0
Asian	Number	0.0	0.0
Hispanic/Latino	Number	0.0	0.0
Black or African American	Number	0.0	0.0
Other Ethnicities[9]	Number	0.0	0.0
Not disclosed	Number	0.0	0.0
Corruption and Bribery			
Incidents of corruption	Number	0.0	0.0
Total monetary losses as a result of legal proceedings associated with corruption and bribery	Dollars ($)	$0.00	$0.00
Ethical Marketing			
Total monetary losses as a result of legal proceedings associated with false marketing claims	Dollars ($)	$0.00	$0.00
Incidents of non-compliance concerning marketing communications	Number	0.0	0.0
Incidents of non-compliance concerning product information and labeling	Number	0.0	0.0

Sustainability Accounting Standards Board

BIOTECHNOLOGY PHARMACEUTICALS

Key Topic	Metric	Unit of Measure	Category	SASB Code	Disclosure Reference
SASB Healthcare: Biotechnology Pharmaceuticals (HC:BP)					
Safety of Clinical Trial Participants	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	n/a	Discussion & Analysis	HC-BP-210a.1	Patient Safety
Safety of Clinical Trial Participants	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	Number	Quantitative	HC-BP-210a.2	Patient Safety
Safety of Clinical Trial Participants	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Reporting currency	Quantitative	HC-BP-210a.3	Patient Safety
Access to Medicines	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	n/a	Discussion & Analysis	HC-BP-240a.1[17]	Access to Medicines
Access to Medicines	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	n/a	Discussion & Analysis	HC-BP-240a.2	See footnote[18]
Affordability & Pricing	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	Number	Quantitative	HC-BP-240b.1[19]	Access to Medicines
Affordability & Pricing	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Percentage (%)	Quantitative	HC-BP-240b.2	Performance Data
Affordability & Pricing	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Percentage (%)	Quantitative	HC-BP-240b.3	See footnote[20]
Drug Safety	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	n/a	Discussion & Analysis	HC-BP-250a.1	Drug Safety
Drug Safety	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Number	Quantitative	HC-BP-250a.2	Drug Safety
Drug Safety	Number of recalls issued, total units recalled	Number	Quantitative	HC-BP-250a.3	Drug Safety
Drug Safety	Total amount of product accepted for takeback, reuse, or disposal	Metric tons (t)	Quantitative	HC-BP-250a.4	Drug Safety
Drug Safety	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Number	Quantitative	HC-BP-250a.5	Drug Safety
Counterfeit Drugs	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	n/a	Discussion & Analysis	HC-BP-260a.1	Counterfeit Drugs
Counterfeit Drugs	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	n/a	Discussion & Analysis	HC-BP-260a.2	Counterfeit Drugs
Counterfeit Drugs	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Number	Quantitative	HC-BP-260a.3	Counterfeit Drugs
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Reporting currency	Quantitative	HC-BP-270a.1	Business Ethics and Transparency
Ethical Marketing	Description of code of ethics governing promotion of off-label use of products	n/a	Discussion & Analysis	HC-BP-270a.2	Ethical Marketing
Employee Recruitment, Development & Retention	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	n/a	Discussion & Analysis	HC-BP-330a.1	Our Employees
Employee Recruitment, Development & Retention	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Rate	Quantitative	HC-BP-330a.2	Our Employees
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit programs for integrity of supply chain and ingredients	Percentage (%)	Quantitative	HC-BP-430a.1	Assessing Suppliers
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Reporting currency	Quantitative	HC-BP-510a.1	Business Ethics and Transparency
Business Ethics	Description of code of ethics governing interactions with health care professionals	n/a	Discussion & Analysis	HC-BP-510a.2	Business Ethics and Transparency
	Activity Metric				
	Number of Patients Treated	Number	Quantitative	HC-BP-000.A	Patient Safety
	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Number	Quantitative	HC-BP-000.B	Drugs in Portfolio and in R&D

17 *Catalyst does not operate in high priority countries as defined by the Access to Medicines Index. FIRDPASE is approved to treat LEMS which is not a high priority disease as defined by the Access to Medicines Index.*
18 *Catalyst does not have a list of products authorized for sale and available on the WHO List of Prequalified Medicinal Products.*
19 *Catalyst has not had to address Hatch-Waxman challenges for ANDAs to date.*
20 *In 2022, the increase in list price for FIRDAPSE® (our only product) was less than 5%. The total increase in list price was also less than 5% in 2021.*

Global Reporting Initiative

Catalyst Pharmaceuticals has reported the information cited in this GRI content index for the period from January 1, 2022 to December 31, 2022 with reference to the GRI Standards.

GRI Indicator	Description	Disclosure Reference
The organization and its reporting practices		
2-1	Organizational Details	About Catalyst Pharmaceuticals
2-2	Entities included in the organization's sustainability reporting	About this Report
2-3	Reporting period, frequency and contact point	About this Report
Activities and workers		
2-6	Activities, value chain and other business relationships	About Catalyst Pharmaceuticals
2-7	Employees	Our Employees
2-8	Workers who are not employees	Form 10K > page 31
Governance		
2-9	Governance structure and composition	Corporate Governance
2-10	Nomination and selection of the highest governance body	Proxy > page 4-10
2-11	Chair of the highest governance body	Board Composition, Proxy > page 4
2-12	Role of the highest governance body in overseeing the management of impacts	Board Composition, Proxy > page 7-11, 13-15
2-13	Delegation of responsibility for managing impacts	Proxy > page 7-11, 13-15
2-14	Role of the highest governance body in sustainability reporting	ESG Oversight & Business Ethics
2-15	Conflicts of interest	ESG Oversight & Business Ethics
2-16	Communication of critical concerns	ESG Oversight & Business Ethics
2-17	Collective knowledge of the highest governance body	Board Composition
2-18	Evaluation of the performance of the highest governance body	Proxy > page 16-20
2-19	Remuneration policies	Executive Incentives, Proxy > page 16-34
2-20	Process to determine remuneration	Executive Incentives, Proxy > page 16-34
Strategy, policies, and practices		
2-22	Statement on sustainable development strategy	CEO Letter
2-23	Policy commitments	ESG Oversight & Business Ethics
2-24	Embedding policy commitments	ESG Oversight & Business Ethics
2-25	Processes to remediate negative impacts	Whistleblower Protections
2-26	Mechanisms for seeking advice and raising concerns	Whistleblower Protections
2-28	Membership associations	Company Profile
Stakeholder engagement		
2-29	Approach to stakeholder engagement	Materiality Assessment
Disclosures on material topics		
3-1	Process to determine material topics	Materiality Assessment
3-2	List of material topics	Materiality Assessment
3-3	Management of material topics	Materiality Assessment

GRI Indicator	Description	Disclosure Reference
Economic performance		
201-1	Direct economic value generated and distributed	Form 10K > page 59-60
201-3	Defined benefit plan obligations and other retirement plans	Form 10K > page 31
Anti-corruption		
205-2	Communication and training about anti corruption policies and procedures	Business Ethics and Transparency
205-3	Confirmed incidents of corruption and actions taken	Business Ethics and Transparency
Anti-competitive behavior		
206-1	Legal actions for anti-competitive behavior, anti trust, and monopoly practices	Business Ethics and Transparency
Employment		
401-1	New employee hires and employee turnover	Our Employees
401-2	Benefits provided to full-time employees that are not provided to temporary or parttime employees	Our Employees
Occupational health and safety		
403-6	Promotion of worker health	Employee Health & Safety
403-9	Work-related injuries	Employee Health & Safety
403-10	Work-related ill health	Employee Health & Safety
Training and education		
404-2	Programs for upgrading employee skills and transition assistance programs	Employee Health & Safety
404-3	Percentage of employees receiving regular performance and career development reviews	Our Employees
Diversity and equal opportunity		
405-1	Diversity of governance bodies and employees	Diversity, Equity, & Inclusion
Non-discrimination		
406-1	Incidents of discrimination and corrective actions taken	Performance Data
Child labor		
408-1	Operations and suppliers at significant risk for incidents of child labor	Performance Data, Human Rights
Rights of indigenous people		
411-1	Incidents of violations involving rights of indigenous peoples	Performance Data
Local communities		
413-1	Operations with local community engagement, impact assessments, and development programs	Community Involvement
Customer health and safety		
416-1	Assessment of the health and safety impacts of product and service categories	Drug Safety
416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	Drug Safety
Marketing and labeling		
417-1	Requirements for product and service information and labeling	Ethical Marketing
417-2	Incidents of non-compliance concerning product and service information and labeling	Performance Data
417-3	Incidents of non-compliance concerning marketing communications	Performance Data

The United Nations Sustainable Development Goals

CATALYST PHARMACEUTICALS UNSDG INDEX

United Nations Sustainable Development Goal ("UN SDG") Alignment

Good Health and Well-Being: Catalyst's mission is to improve the lives of patients living with rare and ultra-rare diseases. By utilizing leading-edge science in search of rare disease therapies, Catalyst is able to develop innovative medicines that improve the well-being of patients suffering from rare diseases. Through rigorous R&D and product testing, Catalyst can develop products to provide patients with innovative and safe medicines. Catalyst is doing their part to ensure medicines are affordable for all with various initiatives aimed at improving medicine affordability and accessibility. Through our work, Catalyst makes a meaningful difference in improving the health and well-being of those in need.

Quality Education: As a benefit to employees looking to excel in their career, Catalyst's management offers education benefits and tuition reimbursement to employees. This benefit can be used for graduate degree programs and compliments the Company's initiatives to develop internal talent.

Gender Equality: At Catalyst, gender equality, diversity, and inclusion are core enablers to bringing the best performance of our employees. We are proud to confirm that approximately 33% of our leadership team are female, 61% of our employees are female, and two of seven members of our C-suite are female. We will continue to evaluate and improve our recruitment policy and strategy, development program, parental leave policy and pay equity review to empower women to thrive in our workforce.

Decent Work and Economic Growth: Through our competitive compensation plans, Catalyst provides good employee benefits and renumeration policies to compensate for the high level of knowledge and training required by many of Catalyst's employees. Catalyst encourages employees develop educational and professional through pursuing additional degrees and offers tuition reimbursement.

Industry, Innovation and Infrastructure: Catalyst demonstrates our commitment to fostering innovation by investing in the science of possibility discovering, developing, and delivering life-changing medicines and solutions to transform patients' lives and address their most important unmet medical needs. Through our own activities and partnerships with organizations, Catalyst is advancing the world of medicine and ensuring society has equal access to medicines.

The United Nations Sustainable Development Goals

CATALYST PHARMACEUTICALS UNSDG INDEX

United Nations Sustainable Development Goal ("UN SDG") Alignment

Reduced Inequalities: Catalyst is reducing inequalities through their access to healthcare and community engagement initiatives aimed at providing affordable and accessible medicines for all patients, regardless of ability to pay. Internal initiatives such as the expanded access programs and Catalyst Pathways demonstrate Catalyst's commitment to affordable medicines, thus improving accessibility and reducing inequalities. Catalyst also demonstrates their commitment to reducing inequalities in the community with donations of time and money to organizations such as Medical Students in Action, Camillus House, and the Woody Foundation.

Climate Action: Catalyst shows active engagement in reducing enterprise-level carbon footprint. As we recognize the importance of environmental stewardship for all stakeholders, Catalyst is looking to implement programmatic changes to environmental management programs and its ability to track environmental data such as GHG emissions, water consumption, and waste generation.

Peace, Justice, and Strong Institutions: Catalyst's Code of Business Ethics clearly lays-out the Company's commitment to maintaining a strong moral fiber. The Company's values of Passion, Trust, and Integrity are interlaced in the core of every action taken by the Company, and Catalyst employees strive to implement these values both personally and professionally.

Partnerships for the Goals: Catalyst partners with various organizations aimed at developing safe and affordable medicines for all. Catalyst's involvement with organizations such as the Pharmaceutical Product Stewardship Work Group and GS1 demonstrate that Catalyst is a leader in promoting product safety throughout the supply chain from R&D to patient use. Commitment to product innovation is illustrated through Catalyst's involvement with organizations such as the Biotechnology Innovation and Organization and BioFlorida. By partnering with these organizations to advance product quality, patient safety, and access to healthcare, Catalyst is leading the way in promoting well-being and reducing inequalities.




Catalyst
pharmaceuticals